Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$297.32
+1.2%
$286.71
$253.30
$335.88
$158.20B0.492.76 million shs2.50 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$826.20
+1.7%
$745.96
$623.78
$935.63
$768.85B0.473.94 million shs2.35 million shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
$64.41
$4.12B0.772.76 million shsN/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+1.18%+0.92%+8.35%-0.31%-8.54%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.67%-2.29%+10.42%+8.42%-9.59%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$297.32
+1.2%
$286.71
$253.30
$335.88
$158.20B0.492.76 million shs2.50 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$826.20
+1.7%
$745.96
$623.78
$935.63
$768.85B0.473.94 million shs2.35 million shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
$64.41
$4.12B0.772.76 million shsN/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
+1.18%+0.92%+8.35%-0.31%-8.54%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+1.67%-2.29%+10.42%+8.42%-9.59%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.35
Hold$309.424.07% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.68
Moderate Buy$948.0614.75% Upside
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AMGN, LLY, and MRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy
10/10/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$876.00 ➝ $879.00
10/9/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$925.00
10/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$875.00 ➝ $948.00
10/8/2025
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+)Buy (B-)
10/8/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$1,028.00 ➝ $1,023.00
10/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price Target$700.00 ➝ $800.00
9/27/2025
Amgen Inc. stock logo
AMGN
Amgen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/26/2025
Amgen Inc. stock logo
AMGN
Amgen
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetUnderperform$261.00 ➝ $272.00
(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.79$30.71 per share9.68$10.93 per share27.20
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.36$14.48 per share57.07$15.03 per share54.97
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$12.2324.3113.902.6018.96%174.71%13.12%11/4/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3054.0026.551.1625.91%92.72%16.89%10/30/2025 (Estimated)
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A

Latest AMGN, LLY, and MRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.01N/AN/AN/A$8.98 billionN/A
10/30/2025Q3 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.42N/AN/AN/A$16.09 billionN/A
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/5/2025Q2 2025
Amgen Inc. stock logo
AMGN
Amgen
$5.28$6.02+$0.74$2.65$8.86 billion$9.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.20%N/A77.84%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%N/A39.22%11 Years
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A

Latest AMGN, LLY, and MRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/1/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.21%8/22/20258/22/20259/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
7.24
1.31
0.98
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.76%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000538.36 million534.27 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.23 millionOptionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionOptionable

Recent News About These Companies

Mirati Therapeutics Stock Price History
Pharma M&A rumour mill grinds out Mirati's name again
Mirati Therapeutics files patent for inhibitors of KRAS g12d

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$297.32 +3.47 (+1.18%)
Closing price 10/15/2025 04:00 PM Eastern
Extended Trading
$298.47 +1.15 (+0.39%)
As of 10/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$826.20 +13.85 (+1.71%)
Closing price 10/15/2025 03:59 PM Eastern
Extended Trading
$826.00 -0.20 (-0.02%)
As of 10/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Mirati Therapeutics stock logo

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.